Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2020
Price :
$35
*
At a glance
- Drugs Abetimus (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms ASPEN
- Sponsors La Jolla Pharmaceutical Company
- 03 Oct 2013 Status changed from recruiting to discontinued as reported by Sri Lanka Clinical Trials Registry.
- 17 Sep 2011 New trial record